NTR Stock Analysis: Nutrien | NYSE
Agricultural Inputs | NYSE, USA | Market Cap: 36.788m USD | 12M Return: 28.6% | CA67077M1086 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 198M
EPS Trend: 2.5%
Qual. Beats: 0
Rev. Trend: -43.6%
Qual. Beats: 4
Warnings
Tailwinds
Seasonality 8.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Nutrien Ltd. (NTR) is a Canadian crop inputs and services provider operating through four segments: Retail, Potash, Nitrogen, and Phosphate. The company was incorporated in 2017 and is headquartered in Saskatoon, Saskatchewan, and trades on the NYSE as a large-cap Materials stock within the GICS Fertilizers & Agricultural Chemicals sub-industry.
The Retail segment distributes crop nutrients, crop protection products, seed, and merchandise, and offers agronomic application, financing services, and proprietary product lines. The Potash segment mines and processes potash ore; the Nitrogen segment produces ammonia, urea, UAN, nitric acid, and related products; and the Phosphate segment manufactures solid and liquid phosphate fertilizers, phosphate feed, and purified phosphoric acid for feed and industrial uses.
Nutrien is vertically integrated across the three primary macronutrient fertilizer categories (potash, nitrogen, and phosphate), combining upstream production with a downstream retail distribution network that serves growers. Its Saskatchewan base is significant for the sector: the province holds the worlds largest commercially developed potash reserves, which is why global potash production is heavily concentrated in the region.
- Potash prices rally on constrained Russian and Belarusian supply
- Nitrogen margins track volatile North American natural gas costs
- Retail segment earnings rise with North American crop demand
| Net Income: 2.38b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 0.72 > 1.0 |
| NWC/Revenue: 16.11% < 20% (prev 14.79%; Δ 1.32% < -1%) |
| CFO/TA 0.08 > 3% & CFO 4.23b > Net Income 2.38b |
| Net Debt (13.1b) to EBITDA (6.30b): 2.09 < 3 |
| Current Ratio: 1.39 > 1.5 & < 3 |
| Outstanding Shares: last quarter (479.8m) vs 12m ago -1.59% < -2% |
| Gross Margin: 31.02% > 18% (prev 29.18%; Δ 1.84% > 0.5%) |
| Asset Turnover: 52.81% > 50% (prev 48.76%; Δ 4.06% > 0%) |
| Interest Coverage Ratio: 5.25 > 6 (EBIT TTM 3.91b / Interest Expense TTM 744.0m) |
| A: 0.08 (Total Current Assets 16.2b - Total Current Liabilities 11.6b) / Total Assets 53.6b |
| B: 0.24 (Retained Earnings 12.7b / Total Assets 53.6b) |
| C: 0.07 (EBIT TTM 3.91b / Avg Total Assets 53.4b) |
| D: 0.94 (Book Value of Equity 25.9b / Total Liabilities 27.6b) |
| Altman-Z'' = 2.81 = A |
| DSRI: 0.99 (Receivables 8.69b/8.09b, Revenue 28.2b/26.0b) |
| GMI: 0.94 (GM 29.18% / 31.02%) |
| AQI: 0.97 (AQ_t 0.27 / AQ_t-1 0.28) |
| SGI: 1.09 (Revenue 28.2b / 26.0b) |
| TATA: -0.03 (NI 2.38b - CFO 4.23b) / TA 53.6b) |
| Beneish M = -3.05 (Cap -4..+1) = AA |
As of September 27, 2026, the stock is trading at USD 72.23 with a total of 3,102,561 shares traded. Over the past week, the price has changed by -6.30%, over one month by -0.84%, over three months by +19.56% and over the past year by +28.55%.
Current recommended Stop Loss: 66.50 (which is 7.9% or 2.6 ATR below the current price).
Nutrien has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy NTR.
- StrongBuy: 11
- Buy: 6
- Hold: 5
- Sell: 0
- StrongSell: 2
| Analysts Target Price | 76.9 | 6.5% |
P/E Trailing = 15.6053
P/E Forward = 15.0602
P/S = 1.3481
P/B = 1.4203
P/EG = 1.982
Revenue TTM = 28.2b USD
EBIT TTM = 3.91b USD
EBITDA TTM = 6.30b USD
Long Term Debt = 9.43b USD (from longTermDebt, last quarter)
Short Term Debt = 2.33b USD (from shortTermDebt, last quarter)
Debt = 14.1b USD (from shortLongTermDebtTotal, last quarter) + Leases 1.34b
Net Debt = 13.1b USD (calculated: Debt 14.1b - CCE 921.0m)
Enterprise Value = 49.9b USD (36.8b + Debt 14.1b - CCE 921.0m)
Interest Coverage Ratio = 5.25 (Ebit TTM 3.91b / Interest Expense TTM 744.0m)
EV/FCF = 23.67x (Enterprise Value 49.9b / FCF TTM 2.11b)
FCF Yield = 4.23% (FCF TTM 2.11b / Enterprise Value 49.9b)
FCF Margin = 7.48% (FCF TTM 2.11b / Revenue TTM 28.2b)
Net Margin = 8.44% (Net Income TTM 2.38b / Revenue TTM 28.2b)
Gross Margin = 31.02% ((Revenue TTM 28.2b - Cost of Revenue TTM 19.5b) / Revenue TTM)
Gross Margin QoQ = 30.07% (prev 27.22%)
Tobins Q-Ratio = 0.93 (Enterprise Value 49.9b / Total Assets 53.6b)
Interest Expense / Debt = 5.29% (Interest Expense 744.0m / Debt 14.1b)
Taxrate = 23.81% (753.0m / 3.16b)
NOPAT = 2.98b (EBIT 3.91b * (1 - 23.81%))
Current Ratio = 1.39 (Total Current Assets 16.2b / Total Current Liabilities 11.6b)
Debt / Equity = 0.54 (Debt 14.1b / totalStockholderEquity, last quarter 25.9b)
Debt / EBITDA = 2.09 (Net Debt 13.1b / EBITDA 6.30b)
Debt / FCF = 6.23 (Net Debt 13.1b / FCF TTM 2.11b)
Total Stockholder Equity = 25.4b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.46% (Net Income 2.38b / Total Assets 53.6b)
RoE = 9.38% (Net Income TTM 2.38b / Total Stockholder Equity 25.4b)
RoCE = 11.22% (EBIT 3.91b / Capital Employed (Equity 25.4b + L.T.Debt 9.43b))
RoIC = 6.87% (NOPAT 2.98b / Invested Capital 43.3b)
WACC = 5.68% (E(36.8b)/V(50.9b) * Re(6.31%) + D(14.1b)/V(50.9b) * Rd(5.29%) * (1-Tc(0.24)))
Discount Rate = 6.31% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -98.23 | Cagr: -1.36%
[DCF] Terminal Value 77.97% ; FCFF base≈1.95b ; Y1≈2.24b ; Y5≈3.29b
[DCF] Fair Price = 76.25 (EV 49.5b - Net Debt 13.1b = Equity 36.4b / Shares 477.2m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 2.45 | EPS CAGR: 0.51% | SUE: 0.73 | # QB: 0
Revenue Correlation: -43.57 | Revenue CAGR: -2.61% | SUE: 0.91 | # QB: 4
EPS current Quarter (2026-09-30): EPS=0.92 | Chg30d=-1.01% | Revisions=-71% | Analysts=16
EPS current Year (2026-12-31): EPS=4.97 | Chg30d=-0.51% | Revisions=-85% | GrowthEPS=+9.1% | GrowthRev=+6.6%
EPS next Year (2027-12-31): EPS=4.95 | Chg30d=+1.12% | Revisions=-32% | GrowthEPS=-0.5% | GrowthRev=-1.2%
[Analyst] Revisions Ratio: -68% (up=7, down=43)